● Recruiting

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Condition: Unresectable Metastatic Colorectal Cancer · Sponsor: Celyad Oncology SA

PhasePhase 1

Planned participants49

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

This description comes directly from the study's public registry record.

Talk to the study team

Celyad Oncology Medical Monitor, MD, PhD · +3210394100 · clinicaltrials@celyad.com

Always discuss trial participation with your own doctor first.

Locations (4)

Moffit Cancer Center	Tampa, Florida, United States	Not Yet Recruiting
Institut Jules Bordet	Brussels, Belgium	Recruiting
UZ Antwerpen	Edegem, Belgium	Recruiting
UZ Leuven	Leuven, Belgium	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03692429